Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ruina Chen

Showing results (11-20 of 16) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 16 results.
Frontiers in Genetics|November 8, 2024
Roles of <i>NR1I3</i> and <i>NR1H4</i> polymorphisms in the susceptibility to antituberculosis drug-induced liver injury in China: a case‒control studyXiaoyan Xu, Ruina Chen, Lihuan Lu, et al.
International Journal of Clinical Pharmacy|February 15, 2025
Genetic polymorphisms and anti-tuberculosis drug-induced liver injury: an umbrella review of the evidenceJingru Cheng, Jia Zhu, Ruina Chen, et al.
Fundamental & Clinical Pharmacology|June 29, 2025
Effects of FECH Gene Polymorphisms and Serum Ferrochelatase Levels on Antituberculosis Drug-Induced Liver Injury in ChinaJingru Cheng, Nannan Wang, Ruina Chen, et al.
Pharmacogenomics|December 10, 2025
Whole exome sequencing identifies rare variants involved in PPIX-metabolizing pathway in anti-TB drug-induced hepatitisYu Wu, Lihuan Lu, Fei Wang, et al.
Pharmacogenetics and Genomics|November 16, 2025
No interaction between genetic variants and DNA methylation of the ferrochelatase gene in relation to antituberculosis drug-induced liver injuryFei Wang, Meiling Zhang, Yu Wu, et al.
The American Journal of Tropical Medicine and Hygiene|July 7, 2026
Impact of Diabetes Mellitus on Drug-Induced Liver Injury during Antituberculosis Therapy: A Prospective Cohort StudyRuina Chen, Yu Wu, Xiaoyan Xu, et al.
Pageof 2

Showing results (11-20 of 16) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 16 results.
Frontiers in Genetics|November 8, 2024
Roles of <i>NR1I3</i> and <i>NR1H4</i> polymorphisms in the susceptibility to antituberculosis drug-induced liver injury in China: a case‒control studyXiaoyan Xu, Ruina Chen, Lihuan Lu, et al.
International Journal of Clinical Pharmacy|February 15, 2025
Genetic polymorphisms and anti-tuberculosis drug-induced liver injury: an umbrella review of the evidenceJingru Cheng, Jia Zhu, Ruina Chen, et al.
Fundamental & Clinical Pharmacology|June 29, 2025
Effects of FECH Gene Polymorphisms and Serum Ferrochelatase Levels on Antituberculosis Drug-Induced Liver Injury in ChinaJingru Cheng, Nannan Wang, Ruina Chen, et al.
Pharmacogenomics|December 10, 2025
Whole exome sequencing identifies rare variants involved in PPIX-metabolizing pathway in anti-TB drug-induced hepatitisYu Wu, Lihuan Lu, Fei Wang, et al.
Pharmacogenetics and Genomics|November 16, 2025
No interaction between genetic variants and DNA methylation of the ferrochelatase gene in relation to antituberculosis drug-induced liver injuryFei Wang, Meiling Zhang, Yu Wu, et al.
The American Journal of Tropical Medicine and Hygiene|July 7, 2026
Impact of Diabetes Mellitus on Drug-Induced Liver Injury during Antituberculosis Therapy: A Prospective Cohort StudyRuina Chen, Yu Wu, Xiaoyan Xu, et al.
Pageof 2